Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin's disease: Long-term results of a randomized trial of radiotherapy alone

Journal of Clinical Oncology

Volumn 19, Issue 11, 2001, Pages 2905-2914

  Duhmke E ^a   Franklin, J ^a   Pfreundschuh, M ^a   Sehlen, S ^a   Willich, N ^a   Ruhl U ^a   Muller R P ^a   Lukas, P ^a   Atzinger, A ^a   Paulus, U ^a   Lathan, B ^a   Ruffer U ^a   Sieber, M ^a   Wolf, J ^a   Engert, A ^a   Georgii, A ^a   Staar, S ^a   Herrmann, R ^a   Beykirch, M ^a   Kirchner, H ^a   Emminger, A ^a   Greil, R ^a   Fritsch, E ^a   Koch, P ^a   Drochtert, A ^a   Brosteanu, O ^a   Hasenclever, D ^a   Loeffler, M ^a   Diehl, V ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RECURRENCE RISK; TREATMENT OUTCOME;

EID: 0035367817     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.11.2905     Document Type: Article

References (35)

1. Towards comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease: The EORTC lymphoma group controlled clinical trials 1964-87
2. Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors
3. Risk factor adapted treatment of Hodgkin's lymphoma: Strategies and perspectives
4. Limited radiation therapy for selected patients with stages IA and IIA Hodgkin's disease
5. Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized study
6. Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease: Six-year results of the EORTC-GPMC controlled clinical trials 'H7-VF', 'H7-F' and H7-U'
7. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate and bleomycinchemotherapy and regional irradiation
8. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients
9. Evidence for a tumoricidal dose level in the radiotherapy of Hodgkin's disease
10. The interplay of radiocurability and tolerance in the irradiation of human cancers
11. An updated dose-response analysis in Hodgkin's disease
12. The optimal dose of radiation in Hodgkin's disease: Analysis of factors affecting in-field disease control
13. Long-term complications of treatment and causes of mortality after Hodgkin's disease
14. Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's Disease
15. Longterm risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood
16. Breast cancer and other second neoplasms after childhood Hodgkin's disease
17. Cardiac injury as late toxicity of mediastinal radiation therapy for Hodgkin's disease patients
18. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease
19. Cardiopulmonary sequelae after treatment of Hodgkin's disease: Increased risk in females
20. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: The role of fractionation
21. Pulmonary morbidity 10-18 years after irradiation for Hodgkin's disease
22. Thyroid diseases after treatment of Hodgkin's disease
23. Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals
24. Patterns of care study outcome studies: Results of the national practice in Hodgkin's disease
25. Randomised trial with early-stage Hodgkin's disease testing 30 Gy vs 40 Gy extended field radiotherapy alone
26. HD-R1: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1)
27. Tables of the number of patients required in clinical trials using the logrank test
28. A prognostic score for advanced Hodgkin's disease: The International Prognostic Factors Project on Advanced Hodgkin's Disease
29. Extended-field radiotherapy in favorable stages IA-IIA Hodgkin's disease (prognostic role of stage)
30. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early stage Hodgkin's disease
31. EBVP chemotherapy + irradiation provides event-free survival superior to subtotal nodal irradiation in favorable clinical stage I-II Hodgkin's disease, but inferior to MOPP-ABV + irradiation in unfavorable cases: The EORTC-GMPC H7 randomised trials
32. Rapidly alternating COPP+ABV+IMEP (CAI) is equally effective as alternating COPP+ABVD (CA) for Hodgkin's disease: Final results of two randomised trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages
33. Dose response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate stage Hodgkin's disease: The German Hodgkin's Lymphoma Study Group
34. Two cycles ABVD plus radiotherapy is more effective than radiotherapy alone in early stage HD: Results of the HD7 trial of the GHSG
35. Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Disease Study Group